Table 2. 3 vs. 6 months of FOLFOX or CAPOX in low-risk and high-risk colon cancer.

Tumor stage	HR DFS (CI)
	FOLFOX (3 m) vs. FOLFOX (6 m)	CAPOX (3 m) vs. CAPOX (6 m)
T1-3 N1	1.10 (0.96–1.26)	0.85 (0.71–1.01)
T4 or N2	1.20 (1.07–1.35)	1.02 (0.89–1.17)
All patients	1.16 (1.06–1.26)	0.95 (0.85–1.06)

HR, hazard ratio; CI, confidence interval; FOLFOX, folinic acid, 5-FU, oxaliplatin; CAPOX, capecitabine, oxaliplatin; DFS, disease free survival.